Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.73 |
| ▸ | RAB9A | P51151 | 6/20 | 0.73 |
| ▸ | MLYCD | O95822 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NAMPT | P43490 | 3/20 | 0.57 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11059466 | 1.00 | NPC1 (0.73) | NPC1RAB9AMLYCDMAPTSMN1; SMN2 | |
| SCHEMBL9337665 | 0.91 | MLYCD (0.76) | NPC1RAB9AMLYCDMAPTMEN1 | |
| SCHEMBL6263516 | 0.91 | MLYCD (0.76) | NPC1RAB9AMLYCDMAPTMEN1 | |
| SCHEMBL12310125 | 0.86 | RAB9A (1.00) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL15214321 | 0.86 | RAB9A (1.00) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL27181403 | 0.86 | RAB9A (1.00) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL822378 | 0.86 | RAB9A (1.00) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL14580374 | 0.86 | RAB9A (1.00) | NPC1RAB9AMAPTSMN1; SMN2MEN1 | |
| SCHEMBL13719442 | 0.85 | SCN10A (0.67) | NPC1RAB9AMLYCDSMN1; SMN2MEN1 | |
| SCHEMBL14825225 | 0.85 | SCN10A (0.60) | NPC1RAB9AMLYCDMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | NPC1 1975/4885RAB9A 3790/4885MLYCD 3429/4885 |
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | COL2A1, BMP4, BMP2 | NPC1 3340/4885RAB9A 3332/4885MLYCD 1324/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | NPC1 1290/4885RAB9A 3885/4885MLYCD 3917/4885 |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, BMP2 | NPC1 3340/4885RAB9A 3332/4885MLYCD 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.